{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:24:41Z","timestamp":1773206681228,"version":"3.50.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1097\/ppo.0b013e318235e0fe","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T22:53:11Z","timestamp":1317768791000},"page":"300-301","source":"Crossref","is-referenced-by-count":16,"title":["Synthetic Vaccine for the Treatment of Lesions Caused by High Risk Human Papilloma Virus"],"prefix":"10.1097","volume":"17","author":[{"given":"Cornelis J.M.","family":"Melief","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.","volume":"8","author":"Melief","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"R2-7-20210203","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.it.2010.12.006","article-title":"Immunotherapy for persistent viral infections and associated disease.","volume":"32","author":"van der Burg","year":"2011","journal-title":"Trends Immunol"},{"key":"R3-7-20210203","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.coi.2010.12.010","article-title":"Therapeutic vaccination against human papilloma virus induced malignancies.","volume":"23","author":"van der Burg","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"R4-7-20210203","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4049\/jimmunol.169.1.350","article-title":"Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.","volume":"169","author":"Zwaveling","year":"2002","journal-title":"J Immunol"},{"key":"R5-7-20210203","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1016\/j.vaccine.2005.04.049","article-title":"Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model.","volume":"23","author":"Vambutas","year":"2005","journal-title":"Vaccine"},{"key":"R6-7-20210203","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-07-1881","article-title":"Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.","volume":"14","author":"Kenter","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1078-0432.CCR-07-1880","article-title":"Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.","volume":"14","author":"Welters","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R8-7-20210203","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"key":"R9-7-20210203","doi-asserted-by":"crossref","first-page":"11895","DOI":"10.1073\/pnas.1006500107","article-title":"Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.","volume":"107","author":"Welters","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-7-20210203","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.immuni.2008.08.004","article-title":"Cancer immunotherapy by dendritic cells.","volume":"29","author":"Melief","year":"2008","journal-title":"Immunity"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00130404-201109000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:55:58Z","timestamp":1618037758000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201109000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e318235e0fe","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}